| scholarly article | Q13442814 |
| P50 | author | Annalisa Berzigotti | Q88161349 |
| Jaime Bosch | Q61107953 | ||
| Jean-François Dufour | Q61977955 | ||
| P2093 | author name string | Andrea De Gottardi | |
| Nasser Semmo | |||
| Guido Stirnimann | |||
| Giuseppe Murgia | |||
| Cristina Margini | |||
| Stefania Casu | |||
| P2860 | cites work | Fat and fiber: how the controlled attenuation parameter complements noninvasive assessment of liver fibrosis | Q85969023 |
| Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease | Q87406034 | ||
| Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases | Q88636602 | ||
| Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy | Q30441653 | ||
| Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B | Q34036808 | ||
| Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies | Q34468844 | ||
| Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. | Q34469981 | ||
| Relaxing the rule of ten events per variable in logistic and Cox regression | Q34593498 | ||
| Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis | Q35131876 | ||
| Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial | Q35142681 | ||
| Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis | Q36236746 | ||
| Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. | Q36903148 | ||
| Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial | Q37217299 | ||
| The clinical use of HVPG measurements in chronic liver disease | Q37590666 | ||
| The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan | Q37932842 | ||
| EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). | Q38837972 | ||
| Non-invasive evaluation of portal hypertension using ultrasound elastography | Q38949475 | ||
| Bacterial Infections Change Natural History of Cirrhosis Irrespective of Liver Disease Severity | Q38950703 | ||
| Basal values and changes of liver stiffness predict the risk of disease progression in compensated advanced chronic liver disease | Q39623958 | ||
| Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? | Q43671252 | ||
| Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis | Q45569255 | ||
| Prognostic Value of Controlled Attenuation Parameter by Transient Elastography | Q47595041 | ||
| Impact of anthropometric features on the applicability and accuracy of FibroScan® (M and XL) in overweight/obese patients. | Q47971448 | ||
| Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study. | Q48273203 | ||
| Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: controlled attenuation parameter for steatosis. | Q50479895 | ||
| Beyond scoring: a modern interpretation of disease progression in chronic liver disease. | Q51018265 | ||
| Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. | Q51171810 | ||
| Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. | Q51655382 | ||
| EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis | Q57782665 | ||
| Expanding consensus in portal hypertension | Q58034372 | ||
| Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study | Q83482709 | ||
| Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography | Q84308242 | ||
| P433 | issue | 8 | |
| P921 | main subject | chronic liver disease | Q5113984 |
| P304 | page(s) | 929-940 | |
| P577 | publication date | 2018-07-24 | |
| P1433 | published in | Hepatology Communications | Q50817751 |
| P1476 | title | Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease | |
| P478 | volume | 2 |
Search more.